Elizabeth A Harrington Selected Research

vistusertib

11/2021	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
10/2019	A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
8/2015	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elizabeth A Harrington Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 03/2004
3	Disease Progression 01/2022 - 05/2015
3	Methylmalonic acidemia 11/2021 - 05/2016
2	Circulating Neoplastic Cells 01/2022 - 12/2018
2	Ovarian Neoplasms (Ovarian Cancer) 12/2021 - 12/2021
2	Carcinogenesis 12/2021 - 03/2004
2	Prostatic Neoplasms (Prostate Cancer) 11/2021 - 01/2015
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 10/2019
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Fatigue 10/2019
1	Vomiting 10/2019
1	Stomach Neoplasms (Stomach Cancer) 10/2019
1	Nausea 10/2019
1	Mucositis 10/2019
1	Dyspepsia (Indigestion) 10/2019
1	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2018
1	Colorectal Neoplasms (Colorectal Cancer) 11/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2017
1	Inborn Errors Metabolism (Inborn Errors of Metabolism) 05/2016
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Lymphoma (Lymphomas) 05/2008
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 05/2008
1	Mycosis Fungoides 05/2008
1	Aneuploidy (Aneuploid) 03/2004

Drug/Important Bio-Agent (IBA)

7	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2015
3	olaparibIBA 12/2021 - 11/2021
3	vistusertibIBA 11/2021 - 08/2015
2	Circulating Tumor DNAIBA 01/2022 - 12/2018
2	AZD9496IBA 01/2022 - 12/2018
2	Estrogen ReceptorsIBA 01/2022 - 12/2018
2	PlatinumIBA 12/2021 - 12/2021
2	Mechanistic Target of Rapamycin Complex 1IBA 11/2021 - 10/2019
2	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 01/2016
2	Phosphotransferases (Kinase)IBA 11/2018 - 03/2004
2	RNA (Ribonucleic Acid)IBA 03/2017 - 01/2016
2	ParaffinIBA 01/2016 - 07/2015
2	Formaldehyde (Formol)FDA Link 01/2016 - 07/2015
1	tofersenIBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 12/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2021
1	abirateroneIBA 11/2021
1	acalabrutinibIBA 11/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 07/2021
1	Rituximab (Mabthera)FDA Link 10/2019
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 10/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	LigandsIBA 12/2018
1	ceralasertibIBA 11/2018
1	Irinotecan (Camptosar)FDA LinkGeneric 11/2018
1	AZD0156IBA 11/2018
1	Biological ProductsIBA 03/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2017
1	Methylmalonyl-CoA MutaseIBA 05/2016
1	Neutralizing AntibodiesIBA 05/2016
1	EnzymesIBA 05/2016
1	AZD4547IBA 01/2016
1	Nucleic AcidsIBA 01/2016
1	PromegaIBA 01/2016
1	Pharmaceutical PreparationsIBA 07/2015
1	carboxyl radical (COO-)IBA 05/2015
1	fostamatinibIBA 05/2015
1	Docetaxel (Taxotere)FDA Link 01/2015
1	AZD8186IBA 01/2015
1	Vorinostat FDA Link 05/2008
1	Histone Deacetylase InhibitorsIBA 05/2008
1	Aurora KinasesIBA 03/2004
1	tozasertibIBA 03/2004

Therapy/Procedure

6	Therapeutics 01/2022 - 12/2018
1	Precision Medicine 01/2022
1	Castration 11/2021
1	Stem Cell Transplantation 10/2019
1	Drug Therapy (Chemotherapy) 01/2015